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Abstract
Background: We present a study protocol for a randomized, double-blind, placebo-controlled trial that investigates
the hypothesis if intervention in the symptomatic phase preceding clinical arthritis (clinically suspect arthralgia
(CSA)) is effective in preventing progression from subclinical inflammation to clinically apparent persistent arthritis.
Currently, rheumatoid arthritis (RA) can be recognized and diagnosed when arthritis (joint swelling) has become
detectable at physical examination. Importantly, at this time, the immune processes have already matured,
chronicity is established, and patients require long-standing treatment with disease-modifying anti-rheumatic drugs.
The TREAT EARLIER trial studies the hypothesis that intervention in the symptomatic phase preceding clinical
arthritis is more often successful in permanent disease modification because of less matured underlying disease
processes.
Methods: A two-level definition to identify patients that are prone to develop RA is used. First, patients should
have CSA and recent-onset arthralgia (< 1 year) that is suspect to progress to RA according to the expertise of the
treating rheumatologist. Second, patients need to have subclinical inflammation of the hand or foot joints at 1.5 T
MRI. The trial aims to recruit 230 participants from secondary care hospital settings across the south-west region of
The Netherlands. Intervention will be randomly assigned and includes a single-dose of intramuscular 120 mg
methylprednisolon followed by methotrexate (increasing dose to 25 mg/week orally) or placebo (both; injection
and tablets) over the course of 1 year. Thereafter, participants are followed for another year. The primary endpoint
is the development of clinically detectable arthritis, either fulfilling the 2010 criteria for RA or unclassified clinical
arthritis of ≥ 2 joints, which persists for at least 2 weeks. DMARD-free status is a co-primary endpoint. The patient-
reported outcomes functioning, along with workability and symptoms, are key secondary endpoints. Participants,
caregivers (including those assessing the endpoints), and scientific staff are all blinded to the group assignment.
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Discussion: This proof-of-concept study is the logical consequence of pre-work on the identification of patients
with CSA with MRI-detected subclinical joint inflammation. It will test the hypothesis whether intervention in
patients in this early phase with the cornerstone treatment of classified RA (methotrexate) hampers the
development of persistent RA and reduce the disease burden of RA.
Trial registration: Dutch Trial Register NL4599 (NTR4853). Registered on 20 October 2014
Keywords: Rheumatoid arthritis, Clinically suspect arthralgia, Subclinical inflammation, MRI, Intervention, Prevention,
Methotrexate, Double-blind, Placebo-controlled, Randomized
Administrative information
Title {1} TREAT Early Arthralgia to Reverse or
Limit Impending Exacerbation to
Rheumatoid arthritis (TREAT EARLIER): a
randomized, double-blind, placebo-
controlled clinical trial protocol
Trial registration {2a and 2b}. Dutch Trial Register: NTR4853/Trial
NL4599. Registered 20 October 2014,
https://www.trialregister.nl/trial/4599.
Protocol version {3} 25-02-2020, protocol version 7
Funding {4} This trial is financially supported by a
ZonMW grant (programma
translationeel onderzoek). The
remaining costs will be covered by the
Department of Rheumatology of the
Leiden University Medical Center.
Author details {5a} E. Niemantsverdriet, study-coordinator,
wrote the manuscript and coordinated
submission, Department of Rheumatol-
ogy, Leiden University Medical Center,
Leiden, The Netherlands
Y.J. Dakkak, study-doctor of the trial, De-
partment of Rheumatology, Leiden Uni-
versity Medical Center, Leiden, The
Netherlands
L.E. Burgers, study-doctor of the trial,
Department of Rheumatology, Leiden
University Medical Center, Leiden, The
Netherlands
F. Bonte-Mineur, rheumatologist who
referred eligible patients for this trial,
Department of Rheumatology, Maas-
stad Hospital, Rotterdam, The
Netherlands
G.M. Steup-Beekman, rheumatologist
who referred eligible patients for this
trial, Department of Rheumatology,
Haaglanden Medical Center - Bronovo,
The Hague, The Netherlands
S.M. van der Kooij, rheumatologist who
referred eligible patients for this trial,
Department of Rheumatology, Haga
Hospital, The Hague, The Netherlands
H.D. Boom, rheumatologist who
referred eligible patients for this trial,
Department of Rheumatology, Spaarne
Gasthuis, Haarlem, The Netherlands
C.F. Allaart, trial-advisor and revised the
manuscript, Department of Rheumatol-
ogy, Leiden University Medical Center,
Leiden, The Netherlands
P.H.P. de Jong, trial-advisor and revised
the manuscript, Department of
Administrative information (Continued)
Rheumatology, Erasmus Medical Center,
Rotterdam, The Netherlands
A.H.M. van der Helm-van Mil, designed
and supervised the study, contributed
to writing of the manuscript and re-
vised the manuscript, Department of
Rheumatology, Leiden University Med-
ical Center, Leiden, The Netherlands,
and Department of Rheumatology,
Erasmus Medical Center, Rotterdam,
The Netherlands
Name and contact
information for the trial
sponsor {5b}
Investigator-initiated clinical trial
Principal investigator: Annette H.M. van
der Helm-van Mil
Leiden University Medical Center,
Albinusdreef 2, 2333 ZA Leiden, The
Netherlands.
Role of sponsor {5c} Principal investigator contributed in
study design, collection, management,
and will contribute to analysis,
interpretation of data, writing the
report, and the decision to submit the
report for publication.
The funding bodies did not have any
role in study design, collection, and
management, nor will have any role in
analysis, interpretation of data, writing
the report, or decision to submit the
report for publication.
For more detailed information we refer to the WHO
trial registration data set: supplementary file 1.
Introduction
Background and rationale {6a}
Rheumatic and musculoskeletal diseases (RMDs) are
among the most prevalent, disabling, and burdensome
non-communicable diseases in Europe and the USA, eli-
citing high costs for healthcare and social security bud-
gets. RMDs are also the number one cause of disability
in Europe. Rheumatoid arthritis (RA) is the commonest
inflammatory cause of disability. It affects 1% of the
population and is characterized by inflammation and de-
struction of the joints; inflammation is typically located
in the hand and foot joints, but other joints are also
regularly inflamed. Pain, stiffness, activity limitation, and
functional disability are direct consequences of
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inflammation and have an impact on physical function-
ing on the individual level and result in work loss. These
disease aspects are the worst at the time of RA diagnosis
and do not revert to normality when treatment is initi-
ated during the phase of clinical arthritis [1–3]. This
causes a large burden of costs for society; direct costs
have considerably escalated due to expensive therapies,
and indirect costs are due to sick leave, work loss, and
disability pensions [4]. New biologic drugs and better
treatment strategies have resulted in improved disease
outcomes during the last decades, and clinically relevant
joint destruction has become infrequent. However, RA
patients still have a chronic disease and RA remains a
remitting and relapsing condition that cannot be cured.
The ultimate treatment strategy prevents the develop-
ment of persistent RA.
The mechanisms underlying arthritis becoming
chronic are poorly understood. The development of RA
is considered to be a multiple-hit process that is largely
taking place before the disease presents with clinically
swollen joints. Different phases in the development of
RA are described by a “European League Against
Rheumatism” (EULAR) taskforce [5, 6]; the phase that
precedes the development of clinically apparent arthritis
is a phase of symptoms. The pattern of symptoms that
characterizes this pre-arthritis phase has been called
clinically suspect arthralgia (CSA) [7]. The clinical ex-
pertise (relying on pattern recognition) of rheumatolo-
gists has been shown accurately in the identification of
patients with arthralgia at risk for RA among all patients
with arthralgia presenting to secondary care (odds ratio
55, sensitivity 80%, specificity 93%) [8]. In this phase of
CSA, patients have not only symptoms such as pain and
stiffness but also functional limitations [9]. Sick leave
and disability pensions are described to rise 6 months
before the diagnosis [4]. Additionally, patients can have
maturing auto-antibody response or increased levels of
pro-inflammatory cytokines in the systemic circulation
[10, 11]. Together, these findings illustrate the relevance
of the CSA phase from the patients’ perspective and the
immunological perspective.
Although clinical joint swelling is per definition absent
in CSA, patients can have subclinical joint inflammation
in the hands or feet, that is, synovitis, tenosynovitis, and/
or inflammation of the subarticular bone, also called
osteitis or bone marrow edema (BME). Magnetic
resonance imaging (MRI) is a sensitive tool to detect
subclinical joint inflammation. Furthermore, the
definition of the presence of (“positivity for”) subclinical
joint inflammation was established by the generation of
a reference atlas from persons from the general
population [12, 13]. Including information on MRI
findings from age-matched symptom-free persons (same
feature, same anatomic location), a highly specific
definition was obtained without losing sensitivity. The
presence of subclinical inflammation in patients with
CSA is associated with a risk of 32% to progress to RA
during the next year [14]; the NPV is 93%, indicating an
acceptable ability to detect RA in a symptomatic pre-
arthritis phase and a low chance to miss patients because
of false-negative results.
The risk of progression to clinical arthritis and RA is
an ongoing research area. At present, no internationally
validated prediction model is available. Patients with
CSA have a higher risk of RA development than patients
with non-specified musculoskeletal symptoms [15]. In
addition to subclinical inflammation, the presence of
auto-antibodies (anti-citrullinated peptide antibody
(ACPA) and rheumatoid factor (RF)) is associated with
the development of clinical arthritis [16]. The data on
the predictive value of ACPA levels are contradictory
[16]. Also, the predictive value of inflammatory response
proteins measured in the systemic circulation is unclear;
most research has so far been conducted on C-reactive
protein (CRP), which is routinely measured in the clinic,
but its predictive value in arthralgia is not undisputed
[16]. Thus, the presence of imaging-detected subclinical
inflammation and auto-antibodies are two validated and
independent risk factors in CSA. Importantly, MRI-
detected subclinical inflammation yields elevated PPVs
for RA development also in ACPA-negative CSA pa-
tients [17, 18].
There are five other placebo-controlled trials aiming at
secondary prevention, namely PRAIRI (2009-010955-29),
APIPPRA (2013-003413-18), ARIAA (2014000555-93),
and STAPRA (2013-05524-42) reported on www.clini-
caltrialsregister.eu, and StopRA (NCT02603146) re-
ported on www.ClinicalTrials.gov. STAPRA has been
stopped prematurely, which studied the effect of inter-
vention with statins. The other ongoing trials study the
effectiveness of intervention with biologic disease-
modifying anti-rheumatic drugs (DMARDs). All men-
tioned trials include participants positive for auto-
antibodies. The TREAT EARLIER trial will include pa-
tients with CSA irrespective of the auto-antibody status.
While ACPA-positive has always been a more severe
subset of RA, up-to-date treatment strategies have made
the disease burden comparable in many aspects for
ACPA-positive and ACPA-negative patients with RA
[19]. This implies that efforts to further improve the dis-
ease outcomes should be proportional to both disease
subsets. Furthermore, for the management of early arth-
ritis, EULAR recommends methotrexate (MTX) as the
first-line therapy, possibly combined with a short course
of corticosteroids, independent of the auto-antibody sta-
tus [20]. Based on observations done in patients with
classified RA (in both APCA-positive and ACPA-
negative RA) that the time to intervention determines
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the efficacy of intervention [21] and the fact that sub-
clinical joint inflammation can now be detected in pa-
tients with CSA, we hypothesize that intervention with
the cornerstone and first-line therapy of RA in this pre-
arthritis phase is effective in preventing arthritis becom-
ing chronic (“chronification”). The present proof-of-
concept study will test this hypothesis with our ultimate
goal to reduce the disease burden of RA.
Objectives {7}
We hypothesize that intervention in the pre-arthritis
phase of CSA with subclinical joint inflammation is ef-
fective in preventing arthritis from becoming chronic
(“chronification”). The present proof-of-concept study
will test this hypothesis with our ultimate goal to reduce
the disease burden of RA (Fig. 1).
Trial design {8}
The present study concerns a randomized placebo-
controlled, parallel, double-blind, superiority clinical
trial (RCT) comparing an 1-year course of MTX com-
bined with a single glucocorticoid intramuscular (IM)
depot injection, with a combination of oral and IM
placebo in patients who are deemed to be at high risk
of developing RA because of having recent-onset CSA
and MRI-detected subclinical inflammation (Fig. 2).
Participants will be treated for 1 year and followed
for another year to observe the development of clinic-
ally detectable arthritis, either fulfilling the 2010 cri-
teria for RA [22] or unclassified clinical arthritis with
a 66-swollen joint count (SJC) of ≥ 2, which persist
for at least 2 weeks. Participants who reach the pri-
mary endpoint will be treated according to the gen-
eral rheumatologic care and in line with the Dutch
and international guidelines [23].
Methods: study setting, participants, and criteria
Study setting {9}
The Leiden University Medical Center (LUMC, The
Netherlands) is the only center where participants
will be enrolled in this single-center study. Screening
with MRI will be done in the LUMC, and for the
duration of the trial, all participants will be treated in
the LUMC. This is done for practical reasons; it al-
lows consistency in the use of MRI (same protocol,
same scanner, same readers) in a patient-friendly
manner because of excellent accessibility to MRI in
the LUMC. It also allows consistency in the deter-
mination of endpoints because all data are collected
by a group of rheumatologists and research nurses
that were trained together.
Despite the fact that the trial will be performed in one
center, recruitment will be done in the South-West re-
gion of The Netherlands. Rheumatologist in all hospitals
in this region (for a list, see supplementary file 2) have
agreed to inform all eligible patients with CSA on the
TREAT EARLIER trial and, with the consent of the pa-
tient, to transfer the patient’s contact details to the study
doctor in the LUMC (Fig. 3). The study doctor, who
should have obtained the medical doctor degree (MD)
Fig. 1 Schematic figure of the objective of the TREAT EARLIER trial
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and is working as a PhD student at The Department of
Rheumatology within the LUMC, is then responsible for
the screening process. The participation of the total re-
gion is an important success factor to identify enough
patients in this very early phase, because patients pre-
senting with CSA are relatively infrequent as the major-
ity of patients already present with swollen joints.
Importantly, our long-standing efforts to allow very early
Fig. 2 Overview of the TREAT EARLIER study
Fig. 3 Screening of eligible patients in the southwest region of The Netherlands
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access for patients with CSA [24] and the commitment
of all hospitals in the region allows to screen and include
sufficient participants in this trial.
Eligibility criteria {10}
We use a two-level definition to identify patients that
are prone to develop RA. First, patients need to have
arthralgia that is suspect to progress to RA according to
the treating rheumatologist, and second, patients should
have a 1.5-T MRI showing local subclinical inflamma-
tion (Fig. 3).
Clinically suspect arthralgia
No single symptom is highly characteristic and
specific for a preclinical phase of RA. However,
patients with symptoms at risk for the development
of RA, in the absence of clinical arthritis, can be
identified by rheumatologists using pattern
recognition. This symptom complex is also called
CSA [25]. For inclusion in our trial, participants need
to have CSA, which is arthralgia of the small joints
and of recent onset (symptoms < 1 year) that
according to the judgment of experienced
rheumatologists are suspect to progress towards RA
over time. The presence of symptoms or signs that
make other diagnoses more likely rules out CSA. We
previously demonstrated that only 6% of all patients
that presented with arthralgia to the rheumatology
outpatient clinic of the LUMC had CSA, and the
clinical expertise had an odds ratio of 55 for
identification of patients at risk for RA [8].
The recognition of the symptom complex that is
described as CSA followed the identification of
different disease phases that precede the development
of RA by the EULAR taskforce in 2012 [5]. According
to this model, there are genetic and environmental
risk factors that play a role where patients are
initially asymptomatic; thereafter, symptoms occur
and eventually, clinical arthritis develops. After the
recognition of CSA, a subsequent EULAR taskforce
has derived a definition of arthralgia suspicious for
the progression of RA. This definition was derived in
2016 and validated thereafter [7, 26]. The TREAT
EARLIER trial was designed in 2014, and therefore,
patients with CSA need to be identified by
rheumatologists using their pattern recognition, but
the fulfillment of the EULAR definition is not a
requirement as this definition did not exist at the
study start.
Hence, CSA is identified based on clinical symptoms
and signs at the first presentation to the outpatient
clinic. The results of laboratory investigations are not
required for the identification of CSA. Moreover,
laboratory assessments are generally not performed by
our general practitioners, as according to the Dutch
guidelines for primary care general practitioners are
discouraged to perform these tests (https://www.nhg.
org/standaarden/volledig/nhg-standaard-artritis).
MRI-detected subclinical inflammation in small joints
Secondly, CSA patients need to have an MRI positive for
subclinical inflammation, which is inflammation that is
present in < 5% of the age-matched general population,
according to two independent readers blinded to clinical
data.
MRI protocol
The screening MRIs will be made of the unilateral wrist,
metacarpophalangeal (MCP)2–5 joints, and
metatarsophalangeal (MTP)1–5-joints at the most
painful side, or the dominant side in case of equally
severe symptoms. MRIs will be performed on a
musculoskeletal (MSK) 1.5-T MRI system (GE, WI,
USA) using a 145-mm coil for the foot and a 100-mm
coil for the hand at the Department of Radiology of the
LUMC. The participants are positioned in a chair beside
the scanner, with the hand or foot fixed in the coil with
cushions. For a detailed scan protocol, refer to supple-
mentary file 3.
The MRIs will be scored for synovitis, tenosynovitis,
and BME (osteitis). Synovitis and osteitis are scored
according to the “outcome measures in rheumatology
clinical trials” (OMERACT)-RA MRI scoring (RAMRIS)
system [27], which is adopted to also include the MTPs.
Tenosynovitis in the MCP, MTP joints, and the wrist,
with post-contrast sequences, is scored as described by
Haavaardsholm et al. [28]. Contrast enhancement
around the extensor tendon sheaths in the MCPs are
scored according to this method [29, 30]. For a detailed
overview, refer to supplementary file 4.
MRI reading
To have two trained MRI readers that are available
all days to drop their work immediately when an
MRI is made to prioritize MRI scoring, every day a
week during the expected inclusion duration of 5
years, we have trained 10 MRI readers. All readers
have become experienced; they have undergone a
training period of 6 months of almost daily MRI
reading and have scored hundreds of MRIs from
CSA and early arthritis patients as well as healthy
controls before finishing the training period. The
interreader and intrareader intraclass correlation
coefficients (ICCs) are all > 0.90 (supplementary file
5). Furthermore, during the screening period, they
will repeatedly determine their intrareader ICCs.
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Inclusion criteria 1. Age ≥ 18 years.
2. Patients without clinically detectable arthritis but
with arthralgia of the small hand or feet joints of
recent onset (< 1 year) that according to the
rheumatologist is suspect to be an early
presentation of RA (this symptom complex is called
CSA).
3. Unilateral MRI of the hand and foot joints, positive
for subclinical inflammation.
4. Ability and willingness to give written informed.
Exclusion criteria
1. Symptoms or signs making diagnoses other than
RA more likely. These are among others; > 6 tender
points or Heberden or Bouchard nodules (the
presence of such characteristics precludes CSA).
2. Presence of, or history of, clinically apparent
arthritis (this precludes CSA).
3. Previous or current treatment with DMARDs or
corticosteroids (this precludes CSA).
4. Contraindications for MRI: certain metal implants,
pacemakers, GFR < 30 ml/min.
5. Pregnancy or the wish to become pregnant,
breastfeeding.
6. Bone marrow hypoplasia.
7. Elevated hepatic enzyme levels (ASAT, ALAT > 3
times normal value).
8. Serum creatinine level > 150umol/l or estimated
clearance of < 60%.
9. Serious infections such as hepatitis, pyelonephritis
in the past 3 months, or chronic infectious diseases
such as chronic chest infections with
bronchiectasis.
Who will take informed consent? {26a} and additional
consent provisions for collection and use of participant
data and biological specimens {26b}
Informed consent will be obtained by research nurses,
who are Good Clinical Practice (GCP)-certificated.
Informed written consent for screening MRIs will be
obtained from all eligible CSA patients (Fig. 3). In case
the MRI scan is positive and patients are willing to
participate in the trial, the trial informed consent will be
signed.
Methods: interventions
Explanation for the choice of comparators {6b}
There is no biological data on the mechanisms involved
in the “chronification” of arthritis, and scientific
evidence to prioritize one specific DMARD is therefore
lacking. The EULAR recommendation for the
management of RA suggests the use of MTX with or
without glucocorticoids as the first choice induction
therapy for patients with newly diagnosed RA [23].
MTX in a dosage of ≥ 20mg/week with folate
substitution has become the anchor drug for RA because
of its efficacy [20, 31–34], acceptable toxicity profile, and
higher retention rate than other DMARDs. MTX is the
anchor drug for RA; it has a favorable benefit/risk ratio
and is cheap; we propose to study the effectiveness of
MTX in patients with CSA. EULAR guidelines for the
treatment of RA are similar for auto-antibody-positive
and auto-antibody-negative RA patients [20]. Likewise,
intervention in the TREAT EARLIER trial will not be
stratified for auto-antibody status.
Whether IM corticosteroids are disease-modifying
drugs is a matter of debate. They can reduce radiological
progression; whether they are able to modify the persist-
ency of the disease is not clear. The SAVE trial showed
no effect of a single glucocorticoid injection on the dis-
ease course [35], whereas the STIVEA trial reported that
a 3-week course of IM glucocorticoid injections resulted
in a significantly higher rate of DMARD-free sustained
remission compared to placebo injections [36]. These
data may indicate that the effect of one or a few IM cor-
ticosteroid injections, without subsequent DMARD ther-
apy, on arthritis persistence is not large. In clinical trials
such as the FINRA-Co study and the BeSt study, how-
ever, it has been demonstrated that combination therapy
of MTX with oral prednisone is superior in early symp-
tom suppression and prevention of radiological damage
compared to MTX monotherapy. The tREACH trial
showed that in undifferentiated arthritis, the initial treat-
ment with a combination of MTX with corticosteroids
was also superior to MTX monotherapy, without a dif-
ference between oral prednisone or an IM depot injec-
tion [37]. The additive effect of low-dose corticosteroids
to conventional DMARDs was also described in a recent
systematic literature review [38]. Based on these obser-
vations, EULAR guidelines recommended that cortico-
steroids can be added at the start, especially as MTX is
slow acting and a short course of corticosteroids can
have a rapid effect. Moreover, it has been shown that
this addition does not affect safety [39]. Thus, in line
with previous and current EULAR recommendations of
the management of RA [20, 23, 33], in the current trial,
corticosteroids will be added to MTX in the form of a
single IM depot injection at the start of MTX.
Intervention description {11a}
In this double-blind RCT, participants will be random-
ized to two arms in an 1:1 ratio. The randomization con-
sists of one IM glucocorticoid injection (120 mg
methylprednisolone or IM placebo injection) followed by
12 months of MTX tablets (or placebo tablets) (Fig. 2).
No other corticosteroid interventions will be allowed
during the trial, unless participants have reached the
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primary endpoint and proceeded to open-label DMARD
therapy.
MTX (or placebo) tablets will be increased in 4 weeks
to 10 tablets/week (25 mg/week). Open-label folic acid
supplementation (5 mg/week) will be added, in line with
the Dutch guidelines of MTX use (https://www.nvr.nl/
richtlijnen/nvr-richtlijnen-standpunten-en-zorgpaden/).
After 45 weeks of 10 tablets/week (MTX or placebo),
tablets will be tapered for 4 weeks and then stopped at
week 53. Participants will be followed for another
12 months.
Criteria for discontinuing or modifying allocated
interventions {11b}
Laboratory tests to monitor possible side effects of
MTX will be performed according to the Dutch
guidelines of MTX (https://www.nvr.nl/richtlijnen/nvr-
richtlijnen-standpunten-en-zorgpaden/). In case of
mild side effects of MTX, either symptom
experienced by the participants or abnormalities in
the laboratory tests (mild increase in ASAT, ALAT,
or mild decrease of leucocyte or thrombocyte counts),
the dosage will be decreased to 5 mg (2 tablets/week),
until an acceptable status is obtained. In case the
dosage will be less than 3 tablets/week (< 7.5 mg
MTX/week), MTX is stopped as in daily practice
dosages lower than 7.5 mg/week is considered not
effective. Then, participants will be treated according
to the treating rheumatologist opinion, however not
with DMARDs or corticosteroids as this would be a
protocol violation. In case of severe side effects, the
treating rheumatologist will stop the MTX (or
placebo). Also, this is in line with the Dutch
guidelines and with the common practice of MTX
treatment in RA. The intention of the trial is to
follow all participants for the total trial period of
24 months. Participants who need to stop the study
medications because of toxicity (or other reasons, e.g.,
wish of participant) will be asked to remain in the
trial for the entire follow-up period.
Strategies to improve adherence to interventions {11c}
MTX is considered as a chemotherapy medication
(despite the low dose of the tablets of 2.5 mg each), and
therefore, it is not allowed for researches to count
tablets at the moment of tablet distribution and return,
according to our pharmacy guidelines. Therefore,
participants will be asked to complete a medication
diary in order to monitor medication adherence, which
will be done for study medication and concomitant non-
steroidal anti-inflammatory drugs (NSAIDs) use (and
will be reviewed every visit).
Relevant concomitant care permitted or prohibited
during the trial {11d}
Concomitant and prohibited treatment
Concomitant treatment with analgesics such as
acetaminophen and/or NSAIDs will be allowed for all
participants, except 24 h before MRI scans [40].
Treatment with DMARDs (conventional synthetic,
biologic DMARDs, or jak-stat inhibitors) or cortico-
steroids (systemic or intra-articular) will be prohibited
during the trial, unless participants reached the pri-
mary endpoint of the trial. Also, any other medicinal
products that, in the supervising physician’s opinion,
may influence underlying disease activity through ef-
fects on immune or inflammatory responses, or both,
are prohibited (with the exception of NSAIDs and
acetaminophen).
All participants will be evaluated for safety. Screening
on toxicity on MTX will be performed by the treating
rheumatologists in line with the Dutch guidelines on
MTX as recommended by the Dutch Society for
Rheumatology (https://www.nvr.nl/richtlijnen/nvr-
richtlijnen-standpunten-en-zorgpaden/).
Concomitant care
Study visits will be scheduled every 4 months for 2 years
follow-up; however, in case a participant has an increase
in symptoms in between two study visits, he/she can be
seen for an additional visit by their rheumatologist
(Fig. 2). In case clinically apparent inflammatory arthritis
is detected, an additional study visit will take place after
2 weeks (and in between the already scheduled study
visits), to check if a participant has reached the primary
endpoint, which is solely based on physical joint examin-
ation. Except for MRI positivity/negativity during screen-
ing, MRI results during the trial will not be
communicated to participants and rheumatologists.
Ultrasound will not be made. Hence, evaluation of the
primary endpoint is not influenced by the results from
imaging.
Provisions for post-trial care {30}
Participants who reach the primary endpoint may
proceed to open-label DMARD therapy, which will be
prescribed by their rheumatologist, and followed
through routine clinical practice. After these first 2 years,
the RCT will be stopped (and unblinded) and partici-
pants will be followed for another 3 years under observa-
tional extension based on regular care (Fig. 2). During
this period, participants who have not achieved the pri-
mary endpoint at month 24 can remain under rheuma-
tologic follow-up. This will be left to the decision of the
treating rheumatologists and participant (shared
decision-making healthcare). If routine follow-up at the
rheumatology outpatient clinic is then stopped,
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participants will be provided with the contact details of
the research team to ensure prompt reporting of new
signs and symptoms of inflammatory arthritis. In
addition, at month 60, all participants will be contacted
again.
All patients are insured during the trial or when an
injury (as a consequence of the trial) originates within 4
years after the trial.
Methods: outcomes {12}
The key primary endpoint is the development of
clinically detectable arthritis, either fulfilling the 2010
criteria for RA [22] or unclassified clinical arthritis with
SJC-66 of ≥ 2 joints, which persists for at least 2 weeks.
This primary endpoint (incidence) will be obtained dur-
ing a 2-year follow-up.
The presence of clinical arthritis (swollen joints) is
based on the physical evaluation of the joints by
rheumatologists. In case of doubt on the presence of
arthritis, it will not be scored. At the start of the trial, all
treating rheumatologists attended a session to verify the
comparability of determining the endpoint. They
demonstrated to have a high interindividual agreement
in the evaluation of the presence or absence of clinical
arthritis at the patient level. The primary endpoint is not
influenced by results from imaging. Ultrasound will not
be done. MRIs made during the trial will be stored
under a randomization number, and the results will not
be reported back to participants or rheumatologists.
Thus, also the MRI results are not included in the
decision making on the clinical endpoint.
The co-primary endpoint is DMARD-free status.
This is assessed at the 2-year follow-up time point
and is defined as the absence of clinically detectable
synovitis at the joint examination in the absence of
DMARD use (including systemic or intra-articular
glucocorticoids).
A key secondary endpoint is functioning (Health
Assessment Questionnaire Disability Index (HAQ-DI)
range 0–3); this will be assessed together with other
patient-reported outcomes (PROs) that are interrelated
but for which no composite measure exists:
 Work productivity and impairment scale (WPAI)
(per item percentage/number and numeric rating
scale (NRS) range 0–10).
 Symptoms: pain (NRS range 0–10), fatigue (NRS
range 0–10), and morning stiffness (NRS range 0–
10, duration in minutes).
Explorative endpoints:
 Tender joint count (TJC-68, range 0–68).
 Hand function: ability to make a fist (left and right,
yes/no), squeeze test (hand, foot, left and right,
positive/negative), and grip strength test with a
dynamometer (range 0–90).
 Global assessment (NRS range 0–10).
 Quality of life: short form-36 (SF-36) (range 0–100),
EuroQol 5D-5level (EQ-5D-5L) (per item, range 1–
5, and visual analog scale (VAS) range 0–100).
 Health appraisal: Brief Illness Perception
Questionnaire short (B-IPQ) (per item, range 0–10),
Rheumatology Attitudes Index (RAI) helplessness
subscale (range 5–25).
 Cost-efficacy measurement by iMTA.
 Radiographic damage of the hands and feet, Sharp-
van der Heijde scores (range 0–448).
 MRI-detected subclinical inflammation on the
unilateral hand and foot, assessed semi-
quantitatively using the RAMRIS score, evaluating
synovitis (range per joint 0–3), BME (also called
osteitis, range per bone 0–3), tenosynovitis (range
per tendon sheath 0–3), and erosions (range per
bone 0–10) [27, 28]. MRI scoring will be done
with known time order and blind to any clinical
data. The scores of synovitis, BME, and tenosyno-
vitis are summed as the total MRI inflammation
score (variable on the patient level). Total scores
will be normalized as described by Sundin et al.
[41]. Furthermore, the MRI data are categorized
as “positive” and “negative” at the joint/location
level and at the patient level. In addition, MRI
data obtained during follow-up will also be cate-
gorized as “positive” and “negative” at the joint/lo-
cation level and subsequently at the patient level.
Categorization in positive/negative will be done
with MRI data of symptom-free persons as a ref-
erence [13], similar to the methodology used at
inclusion.
 Immunological exploratory endpoints: signatures of
immune responses (such as the presence/absence of
ACPA and RF, characteristics of the ACPA
response, and other post-translational modifications
such as anti-carbamylated protein antibodies), levels
of acute-phase reactants (erythrocyte sedimentation
rate, CRP), and inflammatory responses as defined
through the analysis of serum and peripheral blood
cell subsets (RNA expression profiling) and
proteomics.
 (Serious) adverse events ((S) AEs).
Participant timeline {13}
A schematic diagram (Fig. 4) shows the time schedule of
enrolment, intervention assessments, and visits for all
participants. Participants will be followed with 4-
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monthly intervals for 2 years within the double-blind
RCT.
Sample size {14}
Based on the results of the first 120 patients included in
the longitudinal Leiden-CSA cohort and the observation
that 35% of the patients with a positive MRI developed
RA within 6 months of follow-up, and the assumption
that treatment will result in a 50% reduction in RA
development after 2 years, a sample size of 182 patients
is needed to provide 80% power based on a two-sided Z
test with pooled variance and a significance level of 0.05.
Applying a 20% dropout rate results in a total sample
size of 230 patients (115 per treatment arm). This drop-
out rate is calculated based on the data from spring
2018, when the dropout rate within the first study year
was estimated at 14%. Similar sample sizes occur when
calculating the time to DMARD-free status as an
Fig. 4 A schematic diagram of the time schedule of enrolment, intervention assessments, and visits for all participants
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outcome, which is the co-primary endpoint. Based on
our finding that 45% of CSA patients in the Leiden-CSA
cohort had a positive MRI, we anticipate that we have to
screen > 500 CSA patients to identify 230 patients with a
positive MRI.
The sample size was determined for the primary
endpoint. The sample size was not set to detect powered
effects on the number of secondary endpoints that are
assessed. The results from secondary endpoint analyses
will be interpreted cautiously and in relation to the
estimated confidence limits on the actual scale of the
measurements. P value testing will be restricted, and
results that are significant in isolation will be interpreted
less strongly than the sets of results that are mutually
supportive or that support the corresponding primary
endpoint.
Recruitment {15}
Rheumatologists working in all hospitals in the South-
West region of The Netherlands have agreed to inform
all eligible patients with CSA on the TREAT EARLIER
trial and, with the consent of the patient, to transfer the
patients’ contact details to the study doctor in the
LUMC (Fig. 3). The study doctor is then responsible for
the screening process.
It is known from our observational cohort data that
the period of CSA with subclinical inflammation is
sometimes weeks, often months, and infrequently years
[14]. To prevent that patients already progress to clinical
arthritis before inclusion in the trial, the logistic of
screening will be organized as time-efficient and patient-
friendly as possible. This means, among others, that the
MRI will be scored directly after it is made. Both readers
independently send their MRI scoring results to the
study doctor, who compares the results with MRI data
of the reference population as described in supplemen-
tary file 4. The result (positive or negativity) of the
screening MRI will be communicated to the patient and
if the patients prefer, and—after informed written con-
sent—randomization can take place on the same day as
the screening MRI is performed (Fig. 2).
Assignment of interventions: allocation and
blinding
Sequence generation {16a}, concealment mechanism
{16b}, and implementation {16c}
Participants will be enrolled based on a two-level defin-
ition; patients need to have arthralgia that is suspect to
progress to RA according to the treating rheumatologist,
and patients should have MRI-detected inflammation in
the small joints (scored positive by two independent
readers; both readers will be unaware of the clinical data
and communicate their MRI scoring to the study doctor,
without information on the scoring of the other reader).
When both criteria are met and informed written con-
sent is obtained, the study doctor, who is only in charge
of the trial and does not see patients for routine care,
contacts the local pharmacist of the LUMC, who will
take care of the randomization, using a block
randomization scheme to randomly assign the partici-
pants (no stratification will be applied). Once the partici-
pants are randomly assigned, both the IM injection and
study tablets, available in the pharmacy, will be allocated
to the trial participant. IM methylprednisolon or placebo
injection and MTX or placebo tablets are distributed
and packaged similarly. Every 4 months, study tablets
will be in the same way distributed to the trial partici-
pant. All participants and staff involved in the conduct
of the trial will be blind to treatment allocation through-
out the trial.
Who will be blinded {17a} and procedure for unblinding if
needed {17b}
All scientific staff, rheumatologists, research nurses, and
participants will remain blind to the treatment
allocation. Unblinding will occur if medically necessary.
In case the primary endpoint is met, participants will be
treated with open-label DMARD therapy according to
the routine care and the medication choice is left to the
decision of the treating rheumatologist. No unblinding
will take place at this time. In case participants will stop
the study medication because of side effects at an earlier
point in time than the 12-month period, unblinding will
not take place as well (in order to prevent expectation
bias influencing the treating physicians). The data safety
monitoring board (DSMB) receives information blinded
to the treatment allocation; however, if required for
safety issues, the board can ask the pharmacist to pro-
vide them with unblinded data. Otherwise, unblinding
will take place when the last study visit after 2 years of
follow-up of the last included participant is done, and
data quality checks (QCs), as described in the “Data
management {19} and confidentiality {27}” section, are
performed.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Participants will be followed with 4-monthly intervals
for 2 years. Whether there is clinically detectable arth-
ritis will be evaluated at all these visits by physical exam-
ination of the joints by the treating rheumatologists. In
case there is clinically detectable arthritis, an additional
visit will be scheduled after 2 weeks to evaluate whether
the arthritis is persistent (and not self-limiting) and to
verify whether the primary endpoint is met. When this
is the case, a visit will take place that includes all assess-
ments, as also measured at 24 months (Fig. 4).
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At every visit for 2 years, participants undergo a
physical examination and hand function tests. General
markers of inflammation (CRP, erythrocyte
sedimentation rate), complete blood count (hemoglobin,
leukocytes, thrombocytes), and liver and renal function
will be measured at every study visit for 2 years.
Unilateral MRIs and bilateral X-rays of the hands and
feet will be made at study entry; 4, 12, and 24 months;
and when the primary endpoint is achieved. Question-
naires will be completed by the participants at every
study visit for 24 months.
Data collection forms can be obtained upon request by
the study team (treatearlier@Lumc.nl).
Amendment (Protocol version 5, 18-01-2019) includes
a deviation of MRI scan. The 1.5-T MRI scanner that is
used from 2015 onwards is expected to be technically
“end-of-life” after December 2019. It is foreseen that all
participants are enrolled, and thus, inclusion MRI scans
are completed before that time. The MRI scans made
during follow-up can all be obtained either at a 1.5-T or
3-T MRI scanner, depending on the availability at the
radiology department. Although in the MSK literature
the performance of high-end scanners (different 1.5-T,
3-T scanners) is rather comparable [42–45], we will
evaluate the comparability in detecting subclinical joint
inflammation of the two scanners that we will use.
Therefore, we planned to perform both 1.5-T and 3-T
MRIs in up to 30 participants. This will allow us to in-
vestigate the comparability of detecting the presence of
subclinical inflammation in 360 hand/foot joints, 660
bones, and 540 tendon sheaths (one scan depicts 12
small joints, 22 bones, and 18 tendon sheaths). If the
presence of subclinical inflammation at the joint/bone/
tendon sheath level will be similarly portrayed with both
scanners, no further action will be needed. If the 3-T
MRI scanner will be more/less sensitive than the 1.5-T
scanner, a correction factor will be included in the ana-
lyses on the serial MRIs at the time of analyzing the re-
sults on this exploratory endpoint. This correction factor
will be determined based on the data of the 30 scans
that will be made on both machines. The number of par-
ticipants needed to scan on both machines is difficult to
calculate; however, based on the good comparability ob-
served in the literature, the fact that we will make com-
parisons at the joint level, but also accounting for the
fact that multiple joints/bones/tendon sheaths come
from the same participant, we estimate that 30 partici-
pants are sufficient.
Both scans will be performed with at least 2 days in
between to account for sufficient clearance of
intravenous contrast (T1/2 of Dotarem® is 1.4–2.0 h) and
with no more than 1 week in between to reduce the
impact of biological variation. The US “Food and Drug
Administration and the Pharmacovigilance Risk
Assessment Committee” have recently concluded that
no specific conditions have been linked to gadolinium
contrast deposition in the organs [46]. Therefore, it is
safe to administer contrast to the patients based on the
current literature.
Plans to promote participant retention and complete
follow-up {18b}
The intention is to follow all participants for a total
period of 24 months of the RCT at the LUMC.
Participants who need to stop the study medication
because of toxicity (or other reasons, e.g., wish of
participant) will remain in the trial for the entire
follow-up period. In case a participant finds the trial
too demanding, we will ask if an adjusted scheme is
an option, which will at least include the last visit at
the LUMC at 24 months, and if also possible the 12-
month visit.
Participants who will reach the primary endpoint will
be treated by their rheumatologist according to the
Dutch and international guidelines. Participants who
reach the primary endpoint will be asked to complete
the questionnaires at month 24.
Amendment (Protocol version 7, 25-02-2020) in-
cludes the collection of observation data between 24
and 60 months and questionnaires completed by the
participants at 5 years of follow-up. All included par-
ticipants will be contacted 5 years after the inclusion
in the cohort to complete the questionnaires at
month 60. Data from the disease course between
months 24 and 60 will be retrieved from the medical
files if participants consent with the observational ex-
tension study. This extension phase is submitted to
and approved by the medical ethical testing commit-
tee (METC) in 2020, partly in response to comments
of patient partners that suggested to determine if dif-
ferences between the groups will be sustainable in the
long term.
Data management {19} and confidentiality {27}
All participant data gathered at planned and
unscheduled visits will be stored and handled within the
LUMC, Department of Rheumatology, in an electronic
data capture (EDC) platform (ProMISe; NEN7510
certificated based on ISO27001) hosted on a dedicated
secure website by the LUMC. The advanced data
management (ADM) team has extensive experience with
this system. Password, two-step verification manage-
ment, and data exports will be controlled by the ADM
team. Changes to the EDC system once the trial has
begun will be minimized and will be undertaken only
with the full agreement of the principal investigator,
study coordinator, and the METC that is essential to the
successful conduct of the study.
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Participants who consent to the screening but who are
subsequently found to be ineligible will also be recorded
in the EDC system for “Consolidated Standards of
Reporting Trials” (CONSORT) reporting purposes.
These procedures will operate in accordance with the
guidelines for GCP, meeting the requirements of the
medicines and healthcare products regulatory agency.
Participant data will be stored under randomization
number, conform to GCP guidelines. Research nurses
will enter trial data in this platform, which contains
study assessment data, including physical examination
by a research nurse and physician data, routine lab data,
(S) AE and intermittent (co)morbidities) information,
and questionnaires data. The study doctor will monitor
the entered data, which is a first QC, and will verify the
data, checking medical forms to assure that participants
have not met the endpoint and have not received
concomitant medication other than NSAIDs. In
addition, the study doctor will check if all (S) AEs are
reported. A second QC will be performed by the study
coordinator that includes all previous checks as
mentioned for the study doctor. Next, the EDC system
can lock every participant and every study visit, which is
done by the study coordinator after approval of the
principal investigator, conform to GCP guidelines.
Before unblinding (last study visit at 2 years of follow-
up of the last included participant), the EDC platform
will be completely locked by the ADM team under the
supervision of the principal investigator. Thereafter,
unblinding will take place, and the first analyses will be
performed according to the statistical analysis plan.
The data manager (LUMC, Department of
Rheumatology) will supervise the entire process and
keep the original participant clinical forms/information/
data and body material (blood) stored for at least
20 years after the last study visit of the last included
participant. The ADM team, data manager, and
principal investigator directly involved in this trial will
be authorized to access the database but will always be
blinded during the trial. In addition, QC of the data can
also be performed by monitors (employees of LUMC or
hired by the LUMC) and/or Dutch authorities.
All reasonable precautions to maintain the
confidentiality of participants’ identities and protect the
integrity of the data will be taken.
Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Blood samples will be processed, frozen, and stored
anonymously (by randomization number) at − 80 °C
locally in the LUMC for later usage. This concerns
DNA, RNA, serum, and plasma. An explorative
endpoint, as described in the “Outcomes {12}” section, is
analyzing the signatures of immune responses and
inflammatory responses.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
All statistical methods for the primary and secondary
endpoints will be described in the statistical analysis
plan, which will be completed and submitted before
unblinding. Analyses will be based on the intention-to-
treat (ITT) and per-protocol (PP) population. The ITT
population will consist of all participants randomly
assigned to a treatment group. The ITT population will
form the primary analysis population of the trial and will
be used for all primary and secondary efficacy endpoints
and for safety analyses. This strategy is conservative be-
cause it tends to underestimate the difference in the out-
come between the treatment groups, but it respects the
randomization process, is free from bias, and resembles
clinical practice. The PP population will consist of all
participants meeting the study entry criteria, who com-
pleted follow-up and who in the first year after
randomization, or up to a primary event in this period,
have used ≥ 8 study tablets a week (equivalent to at least
20 mg/week MTX) for 80% of the time and used no for-
bidden medication (no systemic or intra-articular ste-
roids or DMARDs outside the study protocol) during
the entire follow-up period. An MTX dose of ≥ 20 mg/
week has been shown to provide optimal efficacy in RA
[31, 32, 34]; therefore, a dose of ≥ 8 study tablets was in-
corporated in the definition. The PP population will con-
sist of participants who strictly adhere to the protocol
and provide an estimate of the true efficacy of the MTX
intervention. All primary and secondary efficacy end-
points will also be analyzed in the PP population. The
primary analysis will be the time to the development of
the primary endpoint. The co-primary endpoint is the
difference in the percentage of patients that achieved
DMARD-free status at 24 months. Significance will be
assessed by a gate-keeping analysis. We do prioritize the
two primary endpoints by testing the primary endpoint
first, and only if this test is significant, the co-primary
endpoint will be tested.
Interim analyses {21b}, methods for additional analyses
(e.g., subgroup analyses) {20b}, methods in analysis to
handle protocol non-adherence, and any statistical
methods to handle missing data {20c}
No interim analyses will be performed during the trial.
Additional analyses, analysis to handle protocol non-
adherence, and any statistical methods to handle missing
data will be described in the statistical analysis plan.
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Plans to give access to the full protocol, participant-level
data, and statistical code {31c}
The full protocol, participant-level data, and statistical
codes will be available from the corresponding author
upon reasonable request.
Oversight and monitoring
Composition of the coordinating center and trial steering
committee {5d} and composition of the data monitoring
committee, its role, and reporting structure {21a}
This trial will be the responsibility of the LUMC and
performed at the LUMC and is thus the coordinating
center. For the roles of everyone involved in this trial
within the LUMC, we refer to the supplementary file 6.
Data monitoring will be performed by the DSMB that
is independent of the principal investigator and has no
competing interests: for further details on composition,
its role, and reporting structure, we refer to the charter
in supplementary file 7.
Adverse event reporting and harms {22}
AEs are clinically significant changes in vital signs,
laboratory test abnormalities, and clinical tolerability of
the study medication. An AE is any adverse medical
change from the subject’s baseline (or pre-treatment)
condition which occurs during the course of a clinical
study, after starting treatment, whether considered
treatment-related or not. AEs may be mentioned spon-
taneously by the participant, or be discovered as a result
of general questioning by the rheumatologist or by phys-
ical examination. AEs will be monitored at each follow-
up visit by asking the participant open-ended questions
to identify any problems that have occurred since the
previous visit. The treating rheumatologist will decide if
and how action should be taken as a response to an AE.
The toxicities to be expected of MTX and a single injec-
tion of methylprednisolon are all well known to the par-
ticipating rheumatologists and generally mild. The
research nurse or study doctor will record the AE(s) in
the clinical record file. As much as possible, each AE
must also be described by its duration (start and end
dates), its frequency (single episode, intermittent, con-
tinuous), its severity (mild, moderate, severe), an assess-
ment of its cause (the underlying study indication,
coexisting disease, concomitant medication, the study
medication, or others), its relationship to the study
medication (unrelated, unlikely, possibly, probably, def-
initely), whether it influenced the course of the study
medication, or whether it required specific therapy.
A serious AE (SAE) is any event that is fatal or life-
threatening, is permanently or significantly disabling, re-
quires or prolongs hospitalization, involves cancer or
congenital anomaly, or occurs with overdose, either
intentional or inadvertent. All SAEs, whether or not
deemed drug related, will be reported directly and com-
municated to the therefore appropriate authority (toet-
singonline.nl and METC).
The DSMB, consisting of three independent physicians
of the LUMC, is able to make trial decisions regarding
major issues like (unexpected) toxicity. All SAE reports
will also be presented to the DSMB.
Frequency and plans for auditing trial conduct {23}
There are no planned auditing trial conducts.
Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethical committees) {25}
Protocol amendments will be communicated to the local
Leiden Den Haag Delft–METC for approval. After
ethical approval, trial participants, registries, and trial
staff will be updated on the protocol modifications
depending on the influence of the changes this could be
by phone, e-mail, face-to-face meetings, and/or
newsletters.
Dissemination plans {31a}
Trial results will be communicated to the participants by
a symposium and newsletters. Trial results will also be
open access reported via publication. We also intend to
inform the Dutch public by a release of the result by
ReumaNederland.
Discussion
This protocol describes the TREAT EARLIER trial that
aims to achieve secondary prevention of the most
common form of inflammatory arthritis, namely RA. It
studies the efficacy of the first-line therapy of RA (MTX,
in combination with methylprednisolon) that is normally
started in the phase of clinically apparent arthritis and is
now evaluated in the phase of CSA with subclinical in-
flammation. MTX is the anchor drug in RA because it is
efficacious, safe, cheap ,and is also the basis for combin-
ation therapies (for instance with glucocorticoids). Ac-
cording to international guidelines, MTX is typically
escalated in 4–6 weeks’ time to 20–25 mg/week [33].
Despite the widespread use and known clinical efficacy,
the mechanism by which MTX (in the described dose)
exerts its effect is incompletely understood. Although
peak plasma concentrations are generally reached within
hours after administration and it has disappeared from
the circulation in approximately 24 h, a time lag occurs
before a clinical benefit is seen. MTX is known for its
slow onset of action, and therefore, in this trial, a single
IM injection of corticosteroids was added at treatment
start for a quicker action. A number of mechanisms are
identified that are potentially involved in the efficacy of
MTX, among which is the depletion of metabolite levels
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that reduce the replication or survival of lymphocytes or
pathogenic cell types. In addition to the antagonism of
folate-dependent processes, stimulation of adenosine sig-
naling (e.g., including FOXP3+ Treg cells), generation of
reactive oxygen species, and downregulation of adhesion
molecule expression and of matrix metalloproteinases,
as wells as the modification of cytokine profiles, have
been described [47]. MTX therefore has pleiotropic ef-
fects that could be important in modifying disease pro-
cesses underlying the progression from arthralgia with
subclinical inflammation to persistent clinical arthritis.
The duration of DMARD use of 1 year in this proof-
of-concept trial is empirical. If it is efficacious, further
studies are needed to determine the optimal dosage and
duration of treatment that is required to achieve per-
manent disease modification.
The follow-up duration of 24 months seems sufficient
for the assessment for the primary endpoint, because
our present data suggest that the majority of CSA pa-
tients who convert to clinically detectable arthritis and
RA do so within 4–6 months [14]. The follow-up in-
cludes 12 months without study medication. Supposed
that MTX would postpone but not prevent the develop-
ment of RA, a medication-free period of 12 months
should be sufficient to detect this. Also, in the PROMPT
trial, only two patients developed RA later than
12 months after cessation of study medication [48].
Nonetheless, the most recently approved amendment to
the protocol (approved February 2020, protocol version
7) includes an observational extension of the trial with a
total follow-up time of 5 years, as the achievement of an
outcome after a relatively short time period of time is
not reflective of the subsequent disease course [49]. A
long-term follow-up is required to evaluate whether re-
sults are sustainable and valuable. Especially, patients
have indicated that the current disease burden is mostly
caused by pain, fatigue, and functional impairments [50];
the decision to extend the follow-up duration is there-
fore in line with the suggestions of patient partners.
After 5 years follow-up, we will assess primary and sec-
ondary endpoints, to evaluate if differences are perman-
ent in the longer term.
The primary endpoint is assessed by physical
examination. Clinical assessments are to some extent
prone to interindividual variation especially when no
efforts are undertaken to promote comparability.
Therefore, reliability sessions have been held at the start
of the trial with all participating rheumatologists. At
these sessions, patients with a broad range of disease
activity, ranging from zero to many swollen joints, were
present and scored by all rheumatologists. Although
some variation occurred in the number of swollen joints
scored in few patients with very active RA (these
patients had many tender and swollen joints), the
presence or absence of swollen joints (clinical arthritis)
at the patient level was very reproducible scored by all
rheumatologists. In addition, the endpoint joint swelling
is observed by two independent rheumatologists; this is
done to reduce interobserver variation and is also
considered valuable when rheumatologists in training
are the treating rheumatologist. Furthermore, to verify
that the endpoint, joint swelling, was not subtle, the RA
criteria [22] should be fulfilled or clinical arthritis should
be clearly present in at least 2 joints at physical
examination and without having information of imaging
modalities. In addition, to further ensure that synovitis is
persisting, the joint swelling (clinical arthritis) should
remain to be present after an interval of 2 weeks.
Although a period longer than 2 weeks would be even
better to assess persistency, delaying treatment with
DMARDs for more than 2 weeks in the presence of
clinical arthritis was considered inappropriate by the
treating rheumatologists. All the mentioned measures
were taken to have a robust assessment of the endpoint
clinical arthritis.
The primary endpoint can be considered as the main
outcome assessed from the perspective of
rheumatologists, but patients indicated that the burden
of RA is best expressed by assessing the domains of
independence (functioning, workability), pain, and
fatigue [50]. The secondary endpoints may therefore be
considered as the benefit from very early treatment from
patients’ perspectives. Moreover, an evaluation 1 year
after the cessation of study medication may be
insufficient to determine if favorable effects are
sustainable over time [49]. Thus, as PROs are considered
most valuable by patients, and as the 2 years
measurement insufficiently assesses sustainability, all
secondary endpoints will also be analyzed again 5 years
after the study start.
This trial was designed in 2014, and risk stratification
was based on the first 120 included Leiden-CSA pa-
tients, which resulted in a risk of 35% to progress to RA
during the next year (PPV) in patients with CSA and a
positive MRI. Based on these numbers, a sample size of
230 participants was required for a well-powered study.
Recently, it was observed that higher PPVs can be ob-
tained when weighting tenosynovitis (particularly, MCP
extensor peritendinitis) and the number of locations
with subclinical inflammation (PPVs up to 63–67%) [17].
This creates opportunities for (subgroup) analyses on
participants with high-risk characteristics.
CSA patients will be enrolled in this trial irrespective
of the auto-antibody status as it has been reported that
with current treatment strategies, the disease burden is
similar in ACPA-positive and ACPA-negative RA pa-
tients [19], and in addition, EULAR recommendations
for the management of early arthritis recommend MTX
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as the first-line therapy, independent of the auto-
antibody status [20]. Nevertheless, there is accumulating
evidence that ACPA-positive and ACPA-negative RA
have different etiopathologies, as underlying genetic [51]
and environmental risk factors differ [52, 53]. Also, sub-
tle differences in symptoms [54] and timelines of the
symptomatic phase that precedes the development of
clinical arthritis have been reported [55]. It is therefore
possible that disease maturation in the symptomatic pre-
arthritis phase differs between the two groups. Conse-
quently, the influence of treatment may be different in
APCA-positive and ACPA-negative CSA. In addition to
adding an adjustment factor, this can be addressed by
stratifying the analyses for ACPA.
Evidence indicating whether or not intervention in the
pre-arthritis phase of CSA reduces disease persistence
will be an important step forward, both for individual
patients and for society. In case very early intervention
with a cheap medication such as MTX will be effective,
this will most likely concomitantly reduce the total level
of pain, the level of functional loss, and the duration of
symptoms. Because of the impact of RA on the lives of
individual patients, such outcomes will be highly rele-
vant for patients and may entail a considerable decrease
in RA-related costs for society. A cost-effectiveness ana-
lysis will be performed at the end of the study.
The results of this proof-of-concept study will be rele-
vant for science. Current research is focused on identify-
ing essential processes that occur during the window of
opportunity. This is done by association studies, evaluat-
ing potential risk factors, such as the presence of inflam-
matory markers, auto-antibody responses, and imaging
features, in patients in different phases of disease devel-
opment. These association studies will be brought to the
next level by a placebo-controlled intervention study.
Studies on the bio-samples that will be obtained during
the trial will increase the comprehension of the inflam-
matory and autoimmune processes relevant for disease
“chronification.” At present, it is not yet known whether
interventions in patients at risk for RA are effective. The
results of this study are positive in case treatment pre-
vents the development of RA or reduces disease persist-
ency. In case of positive findings, further trials on
optimal treatment strategies are required to allow opti-
mized implementation.
Trial status and other additional information
The TREAT EARLIER study trial received ethical
approval on 2 March 2015 (Protocol version 2, 12-01-
2015). The trial is registered at Dutch Trial Register
(NTR4853/Trial NL4599, https://www.trialregister.nl/
trial/4599); 20 October 2014.
The first participant was randomly assigned in April
2015. The RCT is expected to end in September 2021.
– Trial-start: Protocol version 1 (20-10-2014) changes
were required, and version 2 (12-01-2015) was
approved.
– First amendment. Increase samples from 200 to 230
due to expected larger dropout rate than included in
first sample size calculation (20% versus 10%):
protocol version 3 (26-03-2018) changes were
required, and version 4 (31-05-2018) was approved.
– Second amendment. Deviation of MRI scan as the
MRI scanner that is used from 2015 onwards is
expected to be technically “end-of-life” by December
2019: protocol version 5 (18-01-2019) was approved.
Up to 30 participants will be scanned on 1.5-T and
3-T MRI.
– Third amendment includes a collection of
observational data between 24 and 60 months:
protocol version 6 (03-02-2020) changes were
required, and version 7 (25-02-2020) was approved.
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